Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piclidenoson in moderate-to-severe keratoconjunctivitis sicca
NCT00349466Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jan 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in keratoconjunctivitis sicca (KCS) comparing CF101 1mg with Placebo (2 arms). Primary endpoints: Change From Baseline to Week 12 in Schirmer Test Score, Change From Baseline to Week 12 in Tear Break-Up Time and 1 more. Started Jan 2007; status: completed.
02
Drugs
piclidenoson
03
Conditions
keratoconjunctivitis sicca (KCS)
Beyond the preview
Go deeper on NCT00349466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00349466.